Phase I/II Study of Dendritic Cell Therapy Delivered Intratumorally After Cryoablation and Anti-PD-1 Antibody (Pembrolizumab) for Patients With Non-Hodgkin Lymphoma
Latest Information Update: 23 May 2025
At a glance
- Drugs Pembrolizumab (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 09 Dec 2024 Status changed from active, no longer recruiting to completed.
- 11 Sep 2024 Planned End Date changed from 1 Aug 2024 to 1 Aug 2025.
- 11 Sep 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Aug 2025.